Metzger Michael A
Chief Executive Officer
Metzger Michael A has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jul 9, 2026.
On the most recent filing, Metzger Michael A is listed as Chief Executive Officer at Syndax Pharmaceuticals Inc. Inside the rolling window, Metzger Michael A reported no open-market purchases and 4 open-market sales totaling $1.4M in SNDX. The largest disclosed transaction in the window is a sale of 32,375 SNDX shares on Jul 8, 2026, worth $785K.
Companies traded
Other insiders at SNDX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.4M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 8, 2025 | SNDX | Sale | $2.6M |
Frequently asked questions
How many SEC Form 4 filings has Metzger Michael A made?
Metzger Michael A has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.
Which companies does Metzger Michael A trade?
Metzger Michael A has filed SEC Form 4 disclosures for 1 company, including SNDX.
When was Metzger Michael A's most recent SEC Form 4 filing?
Metzger Michael A's most recent SEC Form 4 filing on Tracefour is dated Jul 9, 2026.
What is Metzger Michael A's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Metzger Michael A is listed as Chief Executive Officer.
What is Metzger Michael A's total buy and sell value in the current window?
Inside the rolling retention window, Metzger Michael A bought $0 and sold $1.4M based on SEC Form 4 filings.
What was Metzger Michael A's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 32,375 SNDX shares on 2026-07-08, worth $785K, per SEC Form 4 filings.